Key Highlights

• ARK Invest offloaded 37,977 AMD shares valued at approximately $18.1 million on Wednesday.
• The firm acquired 57,705 Broadcom shares and 69,585 Cerebras Systems shares as semiconductor alternatives.
• ARK divested 59,276 Tempus AI shares via the ARKK ETF, totaling more than $4 million.
• The fund purchased 47,793 Veracyte shares worth $2.1 million across the ARKK and ARKG ETFs.
• Additional portfolio reductions included Twist Bioscience, Roblox, and Brera Holdings.

Cathie Wood's ARK Invest has carried out a significant round of portfolio adjustments this week, divesting millions of dollars in technology holdings while establishing fresh positions in semiconductor and biotechnology companies. ARK publishes its fund-level holdings and daily trades after each trading session, a transparency practice that makes such reallocations visible to the public on a next-day basis.

ARK Exits AMD

The most substantial transaction of the week occurred on Wednesday, when the firm disposed of 37,977 Advanced Micro Devices (AMD) shares valued at approximately $18.1 million. AMD, whose Instinct GPU line competes with Nvidia in AI accelerators, concluded the trading session with a 0.9% decline at $476.67.

The divestment represents a continuation of an established pattern. Wood has been systematically reducing ARK's holdings in the chipmaker over recent months, despite the stock having posted gains exceeding 100% year-to-date.

As part of a semiconductor replacement strategy, ARK acquired 57,705 Broadcom shares — Broadcom designs custom AI chips and networking silicon for large cloud providers — alongside 69,585 shares of Cerebras Systems, the developer of wafer-scale AI processors, during the same trading session. Broadcom concluded trading with a 4.5% gain at $371.54, while Cerebras advanced 2.5% to reach $186.67.

Notwithstanding the sales, ARK continues to hold a larger AMD position than either of its replacement holdings. The flagship ARK Innovation ETF (ARKK) currently holds $193.3 million in AMD, compared with $149.5 million in Cerebras and $95.3 million in Broadcom.

Continued Reduction in Tempus AI Holdings

Thursday saw ARK sell an additional 59,276 Tempus AI shares through the ARKK ETF, a transaction worth slightly more than $4 million. Tempus AI, which applies data analytics to genomic sequencing and precision medicine, went public in 2024. The sale extends a sequence of Tempus AI reductions executed earlier in the week.

The firm simultaneously divested 22,225 Twist Bioscience shares distributed across its ARKK and ARKG ETFs, generating $3.3 million in proceeds — another recurring transaction pattern observed throughout the week. Twist Bioscience specializes in synthetic DNA manufacturing.

Additional, more modest reductions encompassed 1,001 Roblox shares worth $37,597 and 29,385 Brera Holdings shares totaling $116,658.

Increased Investment in the Biotechnology Sector

On the acquisition side, ARK purchased 47,793 Veracyte shares for $2.1 million, distributed between the ARKK and ARKG portfolios, increasing the firm's exposure to the oncological diagnostics specialist, whose genomic tests include Decipher for prostate cancer and Afirma for thyroid nodules.

ARK additionally acquired 5,085 Scribe Therapeutics shares through the ARKG ETF for $161,194, maintaining its consistent biotechnology investment approach. Scribe is a startup developing CRISPR-based gene-editing therapies, and ARK's ETFs have periodically held positions in pre-IPO biotechnology companies.

Strategic Repositioning

Taken together, the transactions show ARK reallocating capital away from select technology holdings and toward genomics and biotechnology — sectors that have consistently anchored Wood's investment philosophy. Wood established ARK's prominence through concentrated positions in genomics, robotics, and artificial intelligence, most notably including an early investment in Tesla. ARKK was among the top-performing U.S. equity funds of 2020 before a multi-year drawdown, and the flagship fund has generated approximately -9% annualized returns over the previous five-year period.

Current trading activity indicates Wood is executing another strategic repositioning, reducing AMD and Tempus AI exposure while expanding positions in Broadcom, Cerebras, and Veracyte. Because ARK discloses its trades each trading day, subsequent disclosures will show whether the reductions and new purchases continue or reverse.

ARK's ARKK ETF advanced 1.87%, while the ARKG ETF climbed 0.85% during Thursday's trading session.